Prenatal drug exposure and neurodevelopmental programming of glucocorticoid signalling

被引:19
|
作者
Franks, Alexis L. [1 ]
Berry, Kimberly J. [2 ]
DeFranco, Donald B. [2 ,3 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA
[3] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol & Neurosci, Pittsburgh, PA USA
关键词
cannabinoid; glucocorticoid; hypothalamic-pituitary-adrenal axis; prenatal; stress; PITUITARY-ADRENAL AXIS; MESSENGER-RNA EXPRESSION; MATERNAL-FETAL-MEDICINE; CANNABINOID RECEPTOR; COCAINE EXPOSURE; COGNITIVE FUNCTION; HPA AXIS; AMERICAN-COLLEGE; ALCOHOL EXPOSURE; SEX-DIFFERENCES;
D O I
10.1111/jne.12786
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prenatal neurodevelopment is dependent on precise functioning of multiple signalling pathways in the brain, including those mobilised by glucocorticoids (GC) and endocannabinoids (eCBs). Prenatal exposure to drugs of abuse, including opioids, alcohol, cocaine and cannabis, has been shown to not only impact GC signalling, but also alter functioning of the hypothalamic-pituitary-adrenal (HPA) axis. Such exposures can have long-lasting neurobehavioural consequences, including alterations in the stress response in the offspring. Furthermore, cannabis contains cannabinoids that signal via the eCB pathway, which is linked to some components of GC signalling in the adult brain. Given that GCs are frequently used in pregnancy to prevent complications of prematurity, and also that rates of cannabis use in pregnancy are increasing, the likelihood of foetal co-exposure to these compounds is high and may have additional implications for long-term neurodevelopment. Here, we present a discussion of GC signalling and the HPA axis, as well as the effects of prenatal drug exposure on these pathways and the stress response, and we explore the interactions between GC and EC signalling in the developing brain and potential for neurodevelopmental consequences.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Infant Health and Neurodevelopmental Outcomes Following Prenatal Exposure to Duloxetine
    Bellantuono, Cesario
    Marini, Alessandra
    Lucarelli, Chiara
    CLINICAL DRUG INVESTIGATION, 2013, 33 (09) : 685 - 688
  • [42] Prenatal exposure to androgens as a factor of fetal programming
    Recabarren, SE
    Sir-Petermann, T
    Maliqueo, M
    Lobos, A
    Rojas-García, P
    REVISTA MEDICA DE CHILE, 2006, 134 (01) : 101 - 108
  • [43] Programming effects of short prenatal exposure to cortisol
    Dodic, M
    Hantzis, V
    Duncan, J
    Rees, S
    Koukoulas, I
    Johnson, K
    Wintour, EM
    Moritz, K
    FASEB JOURNAL, 2002, 16 (09): : 1017 - 1026
  • [44] Prenatal hypergravity exposure: Evidence for developmental programming
    Ronca, AE
    Baer, LA
    Wade, CE
    FASEB JOURNAL, 2005, 19 (04): : A665 - A665
  • [45] PRENATAL ALCOHOL EXPOSURE AND DEVELOPMENTAL PROGRAMMING OF THE KIDNEY
    Moritz, K. M.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2013, 37 : 290A - 290A
  • [46] Can Choline Ameliorate the Neurodevelopmental Effects of Prenatal Exposure to Alcohol?
    Chambers, C. D.
    BIRTH DEFECTS RESEARCH, 2019, 111 (09): : 458 - 458
  • [47] Can choline ameliorate the neurodevelopmental effects of prenatal exposure to alcohol?
    Chambers, C. C.
    NEUROTOXICOLOGY AND TERATOLOGY, 2019, 73 : 80 - 81
  • [48] Prenatal Antipsychotic Exposure and Performance in Neurodevelopmental Outcomes Among Schoolchildren
    Zhang, Jingjing
    Li, Wang
    Yuan, Yuan
    JAMA INTERNAL MEDICINE, 2023, 183 (02) : 167 - 168
  • [49] Variations in Neurodevelopmental Outcomes in Children with Prenatal SSRI Antidepressant Exposure
    Rotem-Kohavi, Naama
    Oberlander, Tim F.
    BIRTH DEFECTS RESEARCH, 2017, 109 (12): : 909 - 923
  • [50] Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: A systematic review
    Gentile, Salvatore
    Galbally, Megan
    JOURNAL OF AFFECTIVE DISORDERS, 2011, 128 (1-2) : 1 - 9